
Cancer Profiling Market (Product: Instruments and Consumables; and Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
Description
Cancer Profiling Market (Product: Instruments and Consumables; and Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
Cancer Profiling Market – Scope of Report
TMR’s report on the global Cancer Profiling Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Cancer Profiling Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Cancer Profiling Market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Cancer Profiling Market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Cancer Profiling Market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Cancer Profiling Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Cancer Profiling Market.
The report delves into the competitive landscape of the global Cancer Profiling Market. Key players operating in the global Cancer Profiling Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Cancer Profiling Market profiled in this report.
Key Questions Answered in Global Cancer Profiling Market Report
- What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
- What are the opportunities in the global Cancer Profiling Market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
The comprehensive report on the global Cancer Profiling Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Cancer Profiling Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Cancer Profiling.
Table of Contents
195 Pages
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Cancer Profiling Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Cancer Profiling Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
- 5. Key Insights
- 5.1. Regulatory Scenario for Cancer Profiling
- 5.2. Cancer Epidemiology, by Region
- 5.3. Technological Advancements in Cancer Profiling Technology
- 5.4. COVID-19 Impact on the Industry
- 6. Global Cancer Profiling Market Analysis and Forecast, by Product
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Product, 2017-2031
- 6.3.1. Instruments
- 6.3.1.1. Immunohistochemistry Analyzers
- 6.3.1.2. In Situ Hybridization Instruments
- 6.3.1.3. Polymerase Chain Reaction Instruments
- 6.3.1.4. DNA Sequencers
- 6.3.1.5. Fragment Analyzers
- 6.3.2. Consumables
- 6.3.2.1. Reagents & Kits
- 6.3.2.2. Others
- 6.4. Market Attractiveness Analysis, by Product
- 7. Global Cancer Profiling Market Analysis and Forecast, by Technology
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Technology, 2017-2031
- 7.3.1. Immunohistochemistry
- 7.3.2. Next Generation Sequencing
- 7.3.3. Polymerase Chain Reaction
- 7.3.4. In Situ Hybridization
- 7.3.5. Microarrays
- 7.3.6. Fragment Analysis
- 7.3.7. Others
- 7.4. Market Attractiveness Analysis, by Technology
- 8. Global Cancer Profiling Market Analysis and Forecast, by Cancer Type
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Cancer Type, 2017-2031
- 8.3.1. Breast Cancer
- 8.3.2. Lung Cancer
- 8.3.3. Colorectal Cancer
- 8.3.4. Prostate Cancer
- 8.3.5. Prostate Cancer
- 8.3.6. Melanoma
- 8.3.7. Others
- 8.4. Market Attractiveness Analysis, by Cancer Type
- 9. Global Cancer Profiling Market Analysis and Forecast, by End-user
- 9.1. Introduction & Definition
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Diagnostic Centers
- 9.3.3. Cancer Research Institutes
- 9.3.4. Others
- 9.4. Market Attractiveness Analysis, by End-user
- 10. Global Cancer Profiling Market Analysis and Forecast, by Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness By Country/Region
- 11. North America Cancer Profiling Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Product, 2017-2031
- 11.2.1. Instruments
- 11.2.1.1. Immunohistochemistry Analyzers
- 11.2.1.2. In Situ Hybridization Instruments
- 11.2.1.3. Polymerase Chain Reaction Instruments
- 11.2.1.4. DNA Sequencers
- 11.2.1.5. Fragment Analyzers
- 11.2.2. Consumables
- 11.2.2.1. Reagents & Kits
- 11.2.2.2. Others
- 11.3. Market Value Forecast, by Technology, 2017-2031
- 11.3.1. Immunohistochemistry
- 11.3.2. Next Generation Sequencing
- 11.3.3. Polymerase Chain Reaction
- 11.3.4. In Situ Hybridization
- 11.3.5. Microarrays
- 11.3.6. Fragment Analysis
- 11.3.7. Others
- 11.4. Market Value Forecast, by Cancer Type, 2017-2031
- 11.4.1. Breast Cancer
- 11.4.2. Lung Cancer
- 11.4.3. Colorectal Cancer
- 11.4.4. Prostate Cancer
- 11.4.5. Prostate Cancer
- 11.4.6. Melanoma
- 11.4.7. Others
- 11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Diagnostic Centers
- 11.5.3. Cancer Research Institutes
- 11.5.4. Others
- 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Product
- 11.7.2. By Technology
- 11.7.3. By Cancer Type
- 11.7.4. By End-user
- 11.7.5. By Country
- 12. Europe Cancer Profiling Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Product, 2017-2031
- 12.2.1. Instruments
- 12.2.1.1. Immunohistochemistry Analyzers
- 12.2.1.2. In Situ Hybridization Instruments
- 12.2.1.3. Polymerase Chain Reaction Instruments
- 12.2.1.4. DNA Sequencers
- 12.2.1.5. Fragment Analyzers
- 12.2.2. Consumables
- 12.2.2.1. Reagents & Kits
- 12.2.2.2. Others
- 12.3. Market Value Forecast, by Technology, 2017-2031
- 12.3.1. Immunohistochemistry
- 12.3.2. Next Generation Sequencing
- 12.3.3. Polymerase Chain Reaction
- 12.3.4. In Situ Hybridization
- 12.3.5. Microarrays
- 12.3.6. Fragment Analysis
- 12.3.7. Others
- 12.4. Market Value Forecast, by Cancer Type, 2017-2031
- 12.4.1. Breast Cancer
- 12.4.2. Lung Cancer
- 12.4.3. Colorectal Cancer
- 12.4.4. Prostate Cancer
- 12.4.5. Prostate Cancer
- 12.4.6. Melanoma
- 12.4.7. Others
- 12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Diagnostic Centers
- 12.5.3. Cancer Research Institutes
- 12.5.4. Others
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Italy
- 12.6.5. Spain
- 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Product
- 12.7.2. By Technology
- 12.7.3. By Cancer Type
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region
- 13. Asia Pacific Cancer Profiling Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Product, 2017-2031
- 13.2.1. Instruments
- 13.2.1.1. Immunohistochemistry Analyzers
- 13.2.1.2. In Situ Hybridization Instruments
- 13.2.1.3. Polymerase Chain Reaction Instruments
- 13.2.1.4. DNA Sequencers
- 13.2.1.5. Fragment Analyzers
- 13.2.2. Consumables
- 13.2.2.1. Reagents & Kits
- 13.2.2.2. Others
- 13.3. Market Value Forecast, by Technology, 2017-2031
- 13.3.1. Immunohistochemistry
- 13.3.2. Next Generation Sequencing
- 13.3.3. Polymerase Chain Reaction
- 13.3.4. In Situ Hybridization
- 13.3.5. Microarrays
- 13.3.6. Fragment Analysis
- 13.3.7. Others
- 13.4. Market Value Forecast, by Cancer Type, 2017-2031
- 13.4.1. Breast Cancer
- 13.4.2. Lung Cancer
- 13.4.3. Colorectal Cancer
- 13.4.4. Prostate Cancer
- 13.4.5. Prostate Cancer
- 13.4.6. Melanoma
- 13.4.7. Others
- 13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Diagnostic Centers
- 13.5.3. Cancer Research Institutes
- 13.5.4. Others
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Product
- 13.7.2. By Technology
- 13.7.3. By Cancer Type
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region
- 14. Latin America Cancer Profiling Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Product, 2017-2031
- 14.2.1. Instruments
- 14.2.1.1. Immunohistochemistry Analyzers
- 14.2.1.2. In Situ Hybridization Instruments
- 14.2.1.3. Polymerase Chain Reaction Instruments
- 14.2.1.4. DNA Sequencers
- 14.2.1.5. Fragment Analyzers
- 14.2.2. Consumables
- 14.2.2.1. Reagents & Kits
- 14.2.2.2. Others
- 14.3. Market Value Forecast, by Technology, 2017-2031
- 14.3.1. Immunohistochemistry
- 14.3.2. Next Generation Sequencing
- 14.3.3. Polymerase Chain Reaction
- 14.3.4. In Situ Hybridization
- 14.3.5. Microarrays
- 14.3.6. Fragment Analysis
- 14.3.7. Others
- 14.4. Market Value Forecast, by Cancer Type, 2017-2031
- 14.4.1. Breast Cancer
- 14.4.2. Lung Cancer
- 14.4.3. Colorectal Cancer
- 14.4.4. Prostate Cancer
- 14.4.5. Prostate Cancer
- 14.4.6. Melanoma
- 14.4.7. Others
- 14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Diagnostic Centers
- 14.5.3. Cancer Research Institutes
- 14.5.4. Others
- 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Product
- 14.7.2. By Technology
- 14.7.3. By Cancer Type
- 14.7.4. By End-user
- 14.7.5. By Country/Sub-region
- 15. Middle East & Africa Cancer Profiling Market Analysis and Forecast
- 15.1. Introduction
- 15.1.1. Key Findings
- 15.2. Market Value Forecast, by Product, 2017-2031
- 15.2.1. Instruments
- 15.2.1.1. Immunohistochemistry Analyzers
- 15.2.1.2. In Situ Hybridization Instruments
- 15.2.1.3. Polymerase Chain Reaction Instruments
- 15.2.1.4. DNA Sequencers
- 15.2.1.5. Fragment Analyzers
- 15.2.2. Consumables
- 15.2.2.1. Reagents & Kits
- 15.2.2.2. Others
- 15.3. Market Value Forecast, by Technology, 2017-2031
- 15.3.1. Immunohistochemistry
- 15.3.2. Next Generation Sequencing
- 15.3.3. Polymerase Chain Reaction
- 15.3.4. In Situ Hybridization
- 15.3.5. Microarrays
- 15.3.6. Fragment Analysis
- 15.3.7. Others
- 15.4. Market Value Forecast, by Cancer Type, 2017-2031
- 15.4.1. Breast Cancer
- 15.4.2. Lung Cancer
- 15.4.3. Colorectal Cancer
- 15.4.4. Prostate Cancer
- 15.4.5. Prostate Cancer
- 15.4.6. Melanoma
- 15.4.7. Others
- 15.5. Market Value Forecast, by End-user, 2017-2031
- 15.5.1. Hospitals
- 15.5.2. Diagnostic Centers
- 15.5.3. Cancer Research Institutes
- 15.5.4. Others
- 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
- 15.7. Market Attractiveness Analysis
- 15.7.1. By Product
- 15.7.2. By Technology
- 15.7.3. By Cancer Type
- 15.7.4. By End-user
- 15.7.5. By Country/Sub-region
- 16. Competition Landscape
- 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
- 16.2. Market Share Analysis, by Company (2022)
- 16.3. Company Profiles
- 16.3.1. Abbott Laboratories
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Product Portfolio
- 16.3.1.3. Financial Overview
- 16.3.1.4. SWOT Analysis
- 16.3.1.5. Strategic Overview
- 16.3.2. Agilent Technologies Inc.
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Product Portfolio
- 16.3.2.3. Financial Overview
- 16.3.2.4. SWOT Analysis
- 16.3.2.5. Strategic Overview
- 16.3.3. F. Hoffmann-La Roche Ltd
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Product Portfolio
- 16.3.3.3. Financial Overview
- 16.3.3.4. SWOT Analysis
- 16.3.3.5. Strategic Overview
- 16.3.4. HTG Molecular Diagnostics, Inc.
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Product Portfolio
- 16.3.4.3. Financial Overview
- 16.3.4.4. SWOT Analysis
- 16.3.4.5. Strategic Overview
- 16.3.5. Illumina, Inc.
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Product Portfolio
- 16.3.5.3. Financial Overview
- 16.3.5.4. SWOT Analysis
- 16.3.5.5. Strategic Overview
- 16.3.6. PerkinElmer Inc.
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Product Portfolio
- 16.3.6.3. Financial Overview
- 16.3.6.4. SWOT Analysis
- 16.3.6.5. Strategic Overview
- 16.3.7. QIAGEN N.V.
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Product Portfolio
- 16.3.7.3. Financial Overview
- 16.3.7.4. SWOT Analysis
- 16.3.7.5. Strategic Overview
- 16.3.8. Siemens Healthineers
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Product Portfolio
- 16.3.8.3. Financial Overview
- 16.3.8.4. SWOT Analysis
- 16.3.8.5. Strategic Overview
- 16.3.9. Sysmex Corporation
- 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.9.2. Product Portfolio
- 16.3.9.3. Financial Overview
- 16.3.9.4. SWOT Analysis
- 16.3.9.5. Strategic Overview
- 16.3.10. Thermo Fisher Scientific Inc.
- 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.10.2. Product Portfolio
- 16.3.10.3. Financial Overview
- 16.3.10.4. SWOT Analysis
- 16.3.10.5. Strategic Overview
- 16.3.11. Hologic, Inc.
- 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.11.2. Product Portfolio
- 16.3.11.3. Financial Overview
- 16.3.11.4. SWOT Analysis
- 16.3.11.5. Strategic Overview
- 16.3.12. Guardant Health
- 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.12.2. Product Portfolio
- 16.3.12.3. Financial Overview
- 16.3.12.4. SWOT Analysis
- 16.3.12.5. Strategic Overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.